Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies.

Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol (2008) 1.51

Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol (2009) 1.48

Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26

Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One (2008) 1.14

Bordetella petrii infection with long-lasting persistence in human. Emerg Infect Dis (2011) 1.05

Bordetella pertussis, Finland and France. Emerg Infect Dis (2006) 1.05

Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04

Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics (2010) 1.04

Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98

Is the Sequenced Bordetella pertussis strain Tohama I representative of the species? J Clin Microbiol (2008) 0.92

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur J Clin Microbiol Infect Dis (2014) 0.91

Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. BMC Infect Dis (2006) 0.88

Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86

Bordetella pertussis in infants hospitalized for acute respiratory symptoms remains a concern. BMC Infect Dis (2013) 0.84

Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. J Clin Microbiol (2011) 0.82

Pulsed-field gel electrophoresis characterization of Bordetella pertussis clinical isolates circulating in Turkey in 2001-2009. Eur J Clin Microbiol Infect Dis (2011) 0.80

Changes in Predominance of Pulsed-Field Gel Electrophoresis Profiles of Bordetella pertussis Isolates, United States, 2000-2012. Emerg Infect Dis (2016) 0.76

Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients. Avicenna J Med Biotechnol (2014) 0.76

Bordetella pertussis polymorphism and pertussis vaccines. Clin Vaccine Immunol (2008) 0.75

Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J (2007) 2.77

Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog (2005) 2.71

Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol (2004) 2.58

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36

Pertussis: not only a disease of childhood. Dtsch Arztebl Int (2008) 2.23

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis (2010) 2.20

Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06

Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02

Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis (2007) 1.77

Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76

Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74

Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73

Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol (2006) 1.69

Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J (2008) 1.69

Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One (2010) 1.61

Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis. J Clin Microbiol (2011) 1.57

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis (2002) 1.57

Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007. J Clin Microbiol (2008) 1.51

Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol (2012) 1.50

Multilocus sequence typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol (2010) 1.47

Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (2002) 1.46

Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis (2014) 1.43

Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines (2009) 1.38

Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol (2008) 1.37

Factors contributing to pertussis resurgence. Future Microbiol (2008) 1.35

Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35

Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33

Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29

New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29

Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microbes Infect (2006) 1.29

Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28

Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26

Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26

Real-time LightCycler PCR for detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol (2002) 1.25

Titration-free massively parallel pyrosequencing using trace amounts of starting material. Nucleic Acids Res (2010) 1.25

Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine (2013) 1.24

Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci (2005) 1.24

The complete genome sequence of Corynebacterium pseudotuberculosis FRC41 isolated from a 12-year-old girl with necrotizing lymphadenitis reveals insights into gene-regulatory networks contributing to virulence. BMC Genomics (2010) 1.24

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol (2005) 1.23

Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet (2006) 1.23

HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One (2007) 1.22

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine (2003) 1.21

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine (2005) 1.17

Diphtheria: a zoonotic disease in France? Vaccine (2009) 1.16

Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One (2008) 1.14

Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin (2009) 1.14

Improving pertussis vaccination. Hum Vaccin (2009) 1.12

Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine (2002) 1.11

Pertussis in Argentina and France. Vaccine (2006) 1.10

Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09

Bordetella holmesii and pertussis diagnosis. Pathology (2013) 1.07

Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05

Bordetella petrii infection with long-lasting persistence in human. Emerg Infect Dis (2011) 1.05

Bordetella pertussis, Finland and France. Emerg Infect Dis (2006) 1.05

Rhinovirus infections in children: a retrospective and prospective hospital-based study. J Med Virol (2009) 1.05

Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04

Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics (2010) 1.04

Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine (2006) 1.04

Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay. Clin Vaccine Immunol (2008) 1.03

Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03

The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis (2012) 1.03

Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03

Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine (2011) 1.03

Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol (2008) 1.02

Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine (2004) 1.02

Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines (2007) 1.01